http://cancergenome.nih.gov/
Director: Kenna Shaw, Ph.D.

TCGA plans to comprehensively characterize the genomic changes (copy number, amplifications, mutations, expressions, and epigenomic changes) in 20 different types of cancer in the next 5 years. TCGA employs statistically robust numbers of clinically annotated high-quality samples to ensure the data are of the highest quality and makes it publicly available. The multi-dimensional datasets from TCGA's analysis of genomic characterization and sequencing of ovarian and brain cancer (glioblastomas) have opened new avenues for targeted discovery and development by:

• Identifying four subtypes of glioblastoma that can be used to stratify patients for trials.
• Mapping genomic changes to specific pathways to provide new insights into the identification of potential new drug targets.
• Developing an analysis pipeline for TCGA data that integrates and displays the data for broad access by basic and clinical researchers.